Is oral thiamine (vitamin B1) supplementation appropriate for treating fatigue in an adult with multiple sclerosis?

Thiamine Supplementation for MS-Related Fatigue

Thiamine supplementation is not currently supported by major clinical guidelines for treating MS-related fatigue, though emerging evidence suggests potential benefit in select cases where thiamine deficiency or dysfunction may be present.

Guideline Perspective

The 2018 ESPEN Clinical Nutrition in Neurology guideline 1 addresses nutritional management in MS but does not specifically recommend thiamine for fatigue management. The guideline explicitly states that "evidence supporting the effectiveness of interventions on the management of fatigue and/or weight loss in advanced stages of progressive illnesses such as MS are lacking."

The guideline does recommend:

• Early detection and treatment of malnutrition by a multidisciplinary team (Grade GPP, 100% consensus) 1
• Dietary advice and oral nutritional supplements when patients cannot meet nutritional needs through food intake (Grade B, 100% consensus) 1
• Adequate provision of nutrients to prevent and correct deficiencies that can compound existing symptoms like fatigue 1

Thiamine Deficiency Context

The 2022 ESPEN Micronutrient Guideline 2 provides comprehensive guidance on thiamine deficiency but does not list MS-related fatigue as an indication for thiamine therapy. FDA labeling 3 indicates thiamine is approved for:

• Beriberi (wet or dry)
• Wernicke's encephalopathy
• Cardiovascular disease due to thiamine deficiency
• Neuritis of pregnancy with severe vomiting
• Patients receiving IV dextrose with marginal thiamine status

MS-related fatigue is not an FDA-approved indication 3.

Emerging Research Evidence

Despite lack of guideline support, preliminary research shows promise:

Key Study Findings:

• 2013 pilot study 4: 15 MS patients with fatigue showed "appreciable improvement" with high-dose thiamine (oral or parenteral) despite normal blood thiamine levels. The authors hypothesized intracellular thiamine transport dysfunction that could be overcome by supranormal concentrations.

• 2017 sulbutiamine study 5: 26 MS patients receiving 400mg daily sulbutiamine (lipophilic thiamine derivative) for 2 months showed significant reduction in Fatigue Impact Scale scores (77 to 60.5, p<0.01). Critical caveat: Improvement occurred primarily in patients on disease-modifying therapy (13/23 improved) versus those not on DMT (0/5 improved).

• 2018 JAMA Neurology review 6 concluded: "At the present time, the only vitamin with sufficient evidence to support routine supplementation for patients with MS is vitamin D." Thiamine was not recommended.

Clinical Reasoning Algorithm

When to Consider Thiamine:

1. First, assess for true thiamine deficiency risk factors 2:

   • Malnutrition or poor oral intake
   • Chronic alcohol consumption
   • Post-bariatric surgery
   • Chronic diuretic therapy
   • Malabsorption disorders
   • Recent refeeding or IV dextrose administration

2. If risk factors present:

   • Measure RBC or whole blood thiamine diphosphate (ThDP) 2
   • If deficient: Treat according to established protocols 2
   • Mild deficiency: 10mg/day orally for 1 week, then 3-5mg daily for 6 weeks
   • Moderate deficiency: 100mg three times daily IV

3. If no deficiency but refractory fatigue:

   • This is off-label use with limited evidence
   • Consider trial only after:
     • Optimizing disease-modifying therapy
     • Excluding other fatigue causes (depression, sleep disorders, anemia, thyroid dysfunction)
     • Ensuring adequate vitamin D supplementation 6
     • Patient counseling about limited evidence

Practical Dosing (If Pursuing Off-Label Trial):

Based on research protocols 4, 5:

• Oral thiamine: 100-300mg daily (far exceeding RDA of 1.1-1.2mg)
• Sulbutiamine: 400mg daily (if available; better CNS penetration)
• Duration: 4-8 week trial
• Monitoring: Fatigue Severity Scale or Fatigue Impact Scale scores

Important Caveats

• No toxicity concerns: Thiamine has no established upper limit; excess is renally excreted 2
• Rare anaphylaxis risk with high-dose IV administration 2
• Mechanism unclear: Normal blood levels in responders 4 suggest possible intracellular transport dysfunction rather than true deficiency
• Effect may require concurrent DMT: The sulbutiamine study 5 showed benefit only in patients on disease-modifying therapy
• Not a substitute for evidence-based MS management: Vitamin D remains the only supplement with sufficient evidence 6

Bottom Line

While thiamine supplementation for MS-related fatigue lacks guideline support and FDA approval, it represents a low-risk intervention that may be considered as adjunctive therapy in patients with refractory fatigue who are already on optimal disease-modifying treatment. Priority should be given to screening for and correcting true thiamine deficiency in at-risk patients 2, ensuring adequate vitamin D supplementation 6, and addressing malnutrition through multidisciplinary nutritional support 1.